New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 1, 2014
12:34 EDTREGN, TWTR, STAA, FOLD, NFLX, SNY, AYIOn The Fly: Midday Wrap
Stocks on Wall Street were sharply higher at midday in the first trading day of the month and the new quarter. The market has not had such a good start to the second half of a year since 2011. The day’s domestic economic data was generally in-line with expectations, while reports from abroad confirmed that manufacturing expanded last month in China and in the eurozone. ECONOMIC EVENTS: In the U.S., two separate manufacturing readings were released. Markit's manufacturing purchasing manager's index for June had a final reading of 57.3, which was a hair below the 57.5 flash estimate but up from May's 56.4 reading. ISM's manufacturing index slipped very slightly to 55.3 in June from May's 55.4 figure. Construction spending increased 0.1% in May, missing the forecast for 0.5% growth. In China, the purchasing manager's index reading from HSBC and Markit came in at 50.7, which was a bit below the preliminary reading but above the 50 mark that indicates expansion for the first time since December. In Europe, Markit's final eurozone manufacturing PMI for June came in at 51.8, which was down from 52.2 in the prior month and below the earlier flash estimate of 51.9, but still indicated expansion in the sector. COMPANY NEWS: Shares of Netflix (NFLX) climbed 6% after Goldman Sachs upgraded the stock in a note to investors earlier today, predicting that Netflix's total worldwide market will more than double over the next three years and its subscriber growth will continue to exceed expectations... Twitter (TWTR) rose more than 4% after hiring Anthony Noto as its new Chief Financial Officer away from Goldman Sachs (GS), which had handled the social network's IPO. Noto served as a Managing Director in the Technology, Media and Telecom group at Goldman since October 2010 after having served as the CFO of the National Football League previously. MAJOR MOVERS: Among the notable gainers was Amicus Therapeutics (FOLD), which rose 23% following upgrades at Leerink and Janney Capital that came a day after the company provided updates on its potential monotherapy for Fabry patients. Also higher was Regeneron (REGN), which advanced 7% after Sanofi (SNY) disclosed in a regulatory filing that it plans to increase its beneficial ownership stake in its smaller pharmaceutical industry peer to 22.5% from 20.5%. Among the noteworthy losers was STAAR Surgical (STAA), which dropped 18% after it received a warning letter from the FDA following the regulator's inspection of a manufacturing plant. Also lower following its earnings reports was lighting solutions maker Acuity Brands (AYI), which fell 13% after its sales and profits missed expectations. INDEXES: Near midday, the Dow was up 134.80, or 0.8%, to 16,961.40, the Nasdaq was up 50.88, or 1.15%, to 4,459.06, and the S&P 500 was up 13.62, or 0.69%, to 1,973.85.
News For NFLX;TWTR;AYI;FOLD;REGN;SNY;STAA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 >>
August 20, 2015
11:22 EDTNFLXNetflix selling accelerates on heavier volume
Subscribe for More Information
11:16 EDTNFLXStocks with call strike movement; FB NFLX
Subscribe for More Information
11:12 EDTTWTRStocks with call strike movement; MU TWTR
Subscribe for More Information
10:19 EDTNFLXNetflix may test uptrend support
Subscribe for More Information
09:17 EDTNFLXDisney hit with another downgrade on TV concerns
Subscribe for More Information
09:08 EDTAYIEnergy Focus price target raised to $23 from $16 at Roth Capital
Subscribe for More Information
August 19, 2015
16:00 EDTNFLX, TWTROptions Update; August 19, 2015
Subscribe for More Information
12:00 EDTTWTRTwitter falls, levels to watch
Subscribe for More Information
10:57 EDTNFLXT-Mobile promotion gives Netflix analyst greater confidence
UBS raised its price target on Netflix (NFLX) to $143 from $116, saying that its confidence in the company's outlook has improved following a promotion undertaken by T-Mobile (TMUS). WHAT'S NEW: T-Mobile recently began offering one free year of Netflix to consumers who switch to its wireless service, UBS analyst Doug Mitchelson wrote in a note to investors today. Mitchelson said that the promotion increases his confidence in the outlook for Netflix's U.S. business. Moreover, he believes that Netflix could "become a standard promotional tool" for wired and wireless broadband providers going forward. Although Netflix's stock "looks very expensive" in the near-term, the company's long-term opportunity is "extraordinary," given the potential size of the global streaming market, the analyst stated. Mitchelson's "upside case" for Netflix shares is $199 while his "downside case" is $55. The downside case assumes Hollywood starts restricting content licensing to streaming services like Netflix in attempt to slow their growth. He raised his price target on the name to $143 from $116 and kept a Buy rating on the shares. WHAT'S NOTABLE: On August 10, research firm Stifel raised its price target on Netflix to $143 from $128, saying that the company's U.S. subscriber base can reach 80M by 2024, above the midpoint of its guidance. PRICE ACTION: In mid-morning trading, Netflix fell 1% to $122.
09:33 EDTNFLX, TWTRActive equity options trading on open
Active equity options trading on open: AAPL BAC FB BA TWTR NFLX WMT BABA
06:01 EDTNFLXNetflix price target raised to $143 from $116 at UBS
UBS analyst Doug Mitchelson raised his price target for Netflix (NFLX) shares to $143 after increasing his longer term revenue assumptions. The streaming service closed yesterday down $1.31 to $124.05. Mitchelson upped his 2020-2026 revenue estimates to reflect his belief that Netflix will successfully monetize its streaming platform beyond just monthly subscription fees, such as bundling and promoting third party services. He has increased confidence in the company's U.S. growth outlook after T-Mobile (TMUS) just launched a promotion for its wireless service that included one free year of Netflix. As competition among broadband providers intensifies, Netflix's inexpensive monthly streaming service could become one of the standard promotional tools, Mitchelson tells investors in a research note. The analyst's "upside case" for Netflix shares is $199 while his "downside case" is $55. The downside case assumes Hollywood starts restricting content licensing to streaming services like Netflix in attempt to slow their growth. Mitchelson keeps a Buy rating on Netflix.
August 18, 2015
16:00 EDTNFLXOptions Update; August 18, 2015
Subscribe for More Information
11:14 EDTNFLXStocks with call strike movement; NFLX VALE
Subscribe for More Information
09:39 EDTNFLXActive equity options trading on open
Subscribe for More Information
August 17, 2015
12:41 EDTTWTRTop universities sell off Twitter shares, Bloomberg reports
Subscribe for More Information
12:23 EDTNFLXStocks with call strike movement; Netflix J.C. Penney
Netflix (NFLX) January 150 call option implied volatility increased 2% to 48, J.C. Penney (JCP) January 10 call option implied volatility increased 1% to 40 according to IVolatility.
12:16 EDTTWTRStocks with call strike movement; RIG TWTR
Subscribe for More Information
12:11 EDTTWTRTwitter's MoPub says native ad use up 8x, TechCrunch reports
Twitter-owned mobile ad exchange MoPub said that the number of apps in its marketplace that use native ads has increased by eight times between June 2014 and June 2015, TechCrunch reports. eCPMS, the amount that advertisers pay for each thousand impressions, are up 73%, and overall spending on native ads increased 387%, the report says. Reference Link
09:38 EDTTWTR, NFLXActive equity options trading on open
Active equity options trading on open: AAPL FB BAC MU NFLX TWTR HUN TSLA BABA MSFT
06:22 EDTREGNPiper's Tenthoff sees select biotech names outperforming in second half
Piper Jaffray analyst Edward Tenthoff expects drug launches, clinical data read-outs and potential partnerships to drive outperformance for select biotech names in the second half of 2015. Despite some recent profit-taking, 2015 has been another strong year for biotech stocks, Tenthoff tells investors in a research note. Names with important second half of the year catalysts include Vertex (VRTX), Regeneron (REGN), Seattle Genetics (SGEN), Exelixis (EXEL), Sarepta (SRPT), Novavax (NVAX), Arrowhead (ARWR), Array BioPharma (ARRY), Alnylam (ALNY), Genocea (GNCA), CymaBay (CBAY), Idera Pharmaceuticals (IDRA), Vitae Pharmaceuticals (VTAE).
1 | 2 | 3 | 4 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use